Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine.
OBJECTIVE
The purpose of this study was to assess psychometric properties of the six-item Headache Impact Text (HIT-6™) across episodic and chronic migraine.


METHODS
Using a migraine screener and number of headache days per month (HDPM), participants from the National Survey of Headache Impact (NSHI) study and the HIT-6 validation study (HIT6-V) were selected for this study. Eligible participants were categorized into three groups: chronic migraine (CM: ≥ 15 HDPM); episodic migraine (EM: < 15 HDPM); non-migraine headaches. Reliability and validity of the HIT-6 were evaluated.


RESULTS
A total of 2,049 survey participants met the inclusion/exclusion criteria for this study. Participants were identified as 6.4% CM; 42.1% EM; 51.5% non-migraine, with respective mean HIT-6 scores: 62.5 ± 7.8; 60.2 ± 6.8; and 49.1 ± 8.7. High reliability was demonstrated with internal consistency (time1/time2) of 0.83/0.87 in NSHI, and 0.82/0.92 in HIT6-V. Intra-class correlation for test-retest reliability was very good at 0.77. HIT-6 scores correlated significantly (p < .0001) with total Migraine Disability Assessment Scale scores (r = 0.56), headache pain severity (r = 0.46), and HDPM (r = 0.29). Discriminant validity analysis showed significantly different HIT-6 scores (F = 488.02, p < .0001) across the groups.


CONCLUSIONS
Results from these analyses confirm that the HIT-6 is a reliable and valid tool for discriminating headache impact across episodic and chronic migraine.
Yang
Min
M
QualityMetric, Inc., 24 Albion Road, Lincoln, RI 02865-4207, USA. myang@analysisgroup.com
Rendas-Baum
Regina
R
Varon
Sepideh F
SF
Kosinski
Mark
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D017281:Cost of Illness; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000523:psychology*; D011594:Psychometrics / Q000379:methods*; D011788:Quality of Life; D015203:Reproducibility of Results; D055815:Young Adult
Neurology. 2003 Aug 12;61(3):375-82
12913201
Headache. 2003 Nov-Dec;43(10):1049-59
14629240
Cephalalgia. 2006 Jun;26(6):742-6
16686915
Qual Life Res. 2003 Dec;12(8):963-74
14651415
Headache. 2003 Apr;43(4):336-42
12656704
Psychol Bull. 1979 Mar;86(2):420-8
18839484
Med Care. 2000 Sep;38(9 Suppl):II73-82
10982092
J Clin Neurol. 2008 Dec;4(4):158-63
19513291
Neurology. 2007 Jan 30;68(5):343-9
17261680
CNS Drugs. 2006;20 Spec no.1:24-36
16841524
Biometrics. 1990 Dec;46(4):1171-8
2085632
Cephalalgia. 2008 May;28(5):484-95
18294250
Neurology. 2008 Sep 9;71(11):848-55
18779513
Cephalalgia. 2005 Mar;25(3):184-90
15689193
Cephalalgia. 2007 Jul;27(7):814-23
17441971
Eur J Neurol. 2005 Mar;12(3):189-93
15693807
Cephalalgia. 2000 Nov;20(9):765-86
11167908
Headache. 2007 Jan;47(1):65-72
17355496
Headache. 2008 Jan;48(1):7-15
18184280
Cephalalgia. 2006 May;26(5):578-88
16674767
Headache. 2001 Jul-Aug;41(7):638-45
11554951
Lancet Neurol. 2006 Feb;5(2):148-157
16426991
J Clin Epidemiol. 2006 Apr;59(4):374-80
16549259
Headache. 2005 May;45(5):429-37
15953259
Neurology. 1994 May;44(5):837-42
8190284
Headache. 2009 Apr;49(4):498-508
19245386
Pain. 2003 Dec;106(3):337-345
14659516
Biomed Pharmacother. 1995;49(10):452-5
8746071
Headache. 2008 Jan;48(1):58-66
18184287
Cephalalgia. 2008 Jan;28(1):26-34
17970768
Cephalalgia. 2003 Jul;23(6):441-50
12807523
Neurology. 2008 Aug 19;71(8):559-66
18711108
Headache. 2008 Jun;48(6):900-13
18047501
Cephalalgia. 1998 Nov;18(9):638-43
9876889
Cephalalgia. 1996 Jun;16(4):231-8; discussion 215
8792034
Neurology. 2001;56(6 Suppl 1):S20-8
11294956
Qual Life Res. 2003 Dec;12(8):981-1002
14651417
Headache. 2010 Mar;50(3):383-95
19817883
Cephalalgia. 2004;24 Suppl 1:9-160
14979299
Headache. 2005 Jun;45(6):638-43
15953295
Cephalalgia. 2007 Dec;27(12):1386-97
17888013